The endocannabinoid system and cardiovascular risk: pathophysiologic role and developing therapeutic interventions.
Sander
Gary E
GE
Section of Cardiology, Department of Medicine, Tulane Medical Center, New Orleans, LA 70112, USA.
Giles
Thomas D
TD
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D063387:Cannabinoid Receptor Antagonists; D063385:Cannabinoid Receptor Modulators / Q000037:antagonists & inhibitors / Q000502:physiology*; D002318:Cardiovascular Diseases / Q000503:physiopathology / Q000517:prevention & control*; D063388:Endocannabinoids; D006801:Humans; D009765:Obesity / Q000188:drug therapy; D010880:Piperidines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D011720:Pyrazoles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000077285:Rimonabant; D018570:Risk Assessment
D063387:Cannabinoid Receptor Antagonists; D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids; D010880:Piperidines; D011720:Pyrazoles; D000077285:Rimonabant